

Chronic Respiratory Disease

An Economic Evaluation of a self-management programme of activity, coping and education (SPACE) for patients with COPD

Journal:	<i>Chronic Respiratory Disease</i>
Manuscript ID	CRD-15-0037.R1
Manuscript Type:	Original Paper
Date Submitted by the Author:	15-Sep-2015
Complete List of Authors:	Dritsaki, Melina; University of Warwick, Health Sciences Johnson, Vicki; Glenfield Hospital, Leicester Respiratory Biomedical Research unit Mitchell, Katy; Glenfield Hospital, Leicester Respiratory Biomedical Research unit Singh, Sally; Glenfield Hospital, Leicester Respiratory Biomedical Research unit Rees, Karen; University of Warwick, Health Sciences
Keywords:	COPD, Cost-effectiveness analysis, Cost-utility analysis, RCT, Self-management, Education
Abstract:	<p>The aim was to undertake a cost-utility analysis of a Self-Management Programme of Activity, Coping and Education (SPACE) for Chronic Obstructive Pulmonary Disease (COPD). The analysis was conducted alongside a six-month randomised controlled trial in 30 primary care settings. The economic analysis used data from 184 patients with confirmed diagnosis of COPD, Forced Expiratory Volume in One second (FEV1)/forced vital capacity (FVC) ratio <0.7 and with grade 2-5 on the Medical Research Council dyspnoea scale. Participants received either a self-management programme consisting of an education manual (SPACEforCOPD) and consultation or usual care. Six-month costs were estimated from the National Health Service and Personal Social Services perspective and Quality-adjusted life years (QALYs) were calculated based on patient responses at baseline and six months.</p> <p>The mean difference in costs between usual care and SPACE FOR COPD programme was -£27.18 (95% CI; -£122.59 to £68.25) while mean difference in QALYs was -0.10 (95% CI; -0.17 to -0.02). The results suggest that the intervention is more costly and more effective than usual care. The probability of the intervention being cost-effective was 97% at a threshold of £20,000/QALY gained. We conclude that the SPACE FOR COPD programme is cost-effective compared to usual care.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For Peer Review

An Economic Evaluation of a self-management programme of activity, coping and education (SPACE)
for patients with COPD

For Peer Review

ABSTRACT

The aim was to undertake a cost-utility analysis of a Self-Management Programme of Activity, Coping and Education (SPACE) for Chronic Obstructive Pulmonary Disease (COPD). The analysis was conducted alongside a six-month randomised controlled trial in 30 primary care settings. The economic analysis used data from 184 patients with confirmed diagnosis of COPD, Forced Expiratory Volume in One second (FEV1)/forced vital capacity (FVC) ratio <0.7 and with grade 2-5 on the Medical Research Council dyspnoea scale. Participants received either a self-management programme consisting of an education manual (SPACEforCOPD) and consultation or usual care. Six-month costs were estimated from the National Health Service and Personal Social Services perspective and Quality-adjusted life years (QALYs) were calculated based on patient responses at baseline and six months.

The mean difference in costs between usual care and SPACE FOR COPD programme was -£27.18 (95% CI; -£122.59 to £68.25) while mean difference in QALYs was -0.10 (95% CI; -0.17 to -0.02). The results suggest that the intervention is more costly and more effective than usual care. The probability of the intervention being cost-effective was 97% at a threshold of £20,000/QALY gained. We conclude that the SPACE FOR COPD programme is cost-effective compared to usual care.

KEYWORDS: COPD, Cost-effectiveness analysis, Cost-utility analysis, RCT, Self-management, Education

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of disability and mortality with more than 3 million people died of COPD in 2012, which is equal to 6% of all deaths globally that year[1]. As well as being recognised to contribute to the substantive deterioration of health-related quality of life (HRQoL) for many patients [2] COPD places a heavy burden on the healthcare system, patients and society overall [3-5].

Non-pharmacological based treatments such as self-management interventions are acknowledged as important strategies to support patients with long-term conditions [6] such as COPD [7]. Although there is no one definition of self-management the broad approach is to teach individuals the skills needed to cope with the disease, ability to recognise and respond to symptoms proactively and adopt a healthy lifestyle as well as manage social interactions[30]. The clinical effectiveness of self-management educational programmes has already been established for a range of chronic illnesses including COPD [8-11]. The most recent Cochrane systematic literature review on self-management showed that it improved HRQoL in patients with COPD compared with usual care [2]. They also showed a reduction in all-cause and COPD-related hospital admissions in those participating in the self-management interventions. The authors of this review, however, claim that they were unable to come to any definitive conclusions, due to the heterogeneity of the studies, in terms of both the study populations, follow-up times, outcome measured, methodology used and the different specification of the “self-management intervention [2]”.

To date only a few studies have attempted to evaluate the cost-effectiveness of self-management programmes for people with COPD. Some studies reported only the programme costs [8,12,13]. The evidence suggests that self-management programmes are cost-effective in improving patient outcomes and reducing cost [9,14,15]. These studies have taken different methodological approaches and differ on the primary outcome considered [16].

A randomised controlled trial was carried out to determine the short-term (baseline to 6 weeks) and medium-term (6 weeks to 6 months) effectiveness of a Self-management Programme of Activity, Coping and Education for COPD (SPACE FOR COPD) on patient outcomes, compared with usual care alone. Full clinical results of this trial are reported elsewhere [17]. In brief, at six weeks, there were significant differences between groups in Chronic Respiratory Questionnaire-Self-Reported (CRQ-SR) dyspnoea, fatigue and emotion scores, exercise performance, anxiety, and disease knowledge. However there was no between-group difference in change of the primary outcome measure (CRQ-SR dyspnoea) at six months. However, exercise performance, anxiety and self-reported smoking status were significantly different between groups, in favour of the intervention.

The aim of this study was therefore to undertake a cost-utility analysis to examine the cost-effectiveness of SPACE FOR COPD versus usual care at six months.

METHODS

Study Design

This was a single-centre, investigator-blinded, randomised controlled trial conducted with six months follow-up, which took place December 2009- April 2012. 184 Participants were randomised to either SPACE FOR COPD (n=89) or to usual care (n=95). Practices screened patient registers to identify eligible candidates. To be included, participants were required to: 1) have a diagnosis of COPD confirmed by spirometry, with a forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) ratio <0.7; 2) be grade 2-5 on the Medical Research Council (MRC) dyspnoea scale [31]; and 3) have been clinically stable for four weeks. Individuals were excluded if they; 1) were unable to undertake an exercise regime due to neurological, musculoskeletal or cognitive co-morbidities; 2) unable to read English to the reading age of an eight year old; and 3) had completed pulmonary rehabilitation within the previous 12 months.

SPACE FOR COPD

Participants randomised to SPACE FOR COPD were introduced to the programme by a physiotherapist during a 30-45 minute consultation, using principles of Motivational Interviewing. This comprehensive programme has been described elsewhere [17,18] and is structured around the SPACE FOR COPD manual. Briefly, the manual contains educational material on a wealth of topics and a home exercise programme. Acquisition of skills is promoted through goal-setting strategies, coping planning and case studies. The manual advises on training progression, and includes an action plan for exacerbation management [18].

Participants' needs were discussed and goal setting strategies were introduced at initial consultation. It was anticipated that participants would work through the manual in approximately six weeks; Participants received two telephone contacts at two and four weeks into the programme from the physiotherapist, with the aim of reinforcing skills and providing encouragement to

progress. There was no further contact between the physiotherapist and participant after the telephone contact at four weeks.

Usual care

All study participants continued to receive usual care for their COPD management. Within primary care, all participants were managed under a general practitioner (GP) and practice team. No participants received pulmonary rehabilitation during the study period.

Health outcomes

Participants were asked to describe their HRQoL at baseline, six weeks and six months post-randomisation by using the EuroQol EQ-5D-3L instrument [29]. The EQ-5D is the generic, multi-attribute, preference-based measure preferred by National Institute for Health and Care Excellence (NICE) [23] for broader cost-effectiveness comparative purposes. The EQ-5D consists of two principal measurement components. The first is a descriptive system, which defines HRQoL in five dimensions: 'mobility', 'self-care', 'usual activities', 'pain/discomfort' and 'anxiety/depression'. A total of 243 health states are generated by the EQ-5D descriptive system. For the purposes of this study, the York A1 tariff was applied to each set of responses to the descriptive system to generate an EQ-5D utility score [19]. Resulting utility scores range from scores -0.59 to 1.0, with '0' representing death and '1' representing full health. Utility values < 0 indicate health states worse than death. The second measurement component of the EQ-5D, the vertical visual analogue scale (VAS) ranging from 100 (best imaginable health state) to 0 (worst imaginable health state), was also included.

Collection and valuation of resource-use cost data

Data on the resource items and services used for the intervention and the control arm were collected over the six-month time horizon. Data on consumable use (SPACE FOR COPD manual), introduction to SPACE FOR COPD and telephone contact duration were recorded prospectively in research/study records. Healthcare data were obtained through three primary sources. First, the hospital records were investigated to capture all resources relating to the participants' use of health and social care services over the six month study period. Second, GP records were also analysed to capture the use of primary healthcare and social care services. Thirdly, patients were asked at their follow-up research appointment to detail any healthcare contacts. The following data were captured: the dates, duration, and reasons for healthcare contacts (classified as respiratory or non-respiratory related), the healthcare professional involved, mode of delivery (i.e. clinic, home visit or telephone contact) for all appointments, investigations, admissions, emergency department visits, and referrals. Information was obtained from these three data sources (hospital, GP and patient) and triangulated to give the most likely, overall healthcare resource use. Medication use was obtained from prescription and medication records from GP sources. Type, dose and frequency of medications prescribed were recorded (including oxygen therapy) and classified as respiratory or non-respiratory medications.

The unit cost for resources used for the implementation of SPACE FOR COPD were mainly obtained from the SPACE FOR COPD study records, apart from the unit costs of physiotherapists' time obtained from the Personal Social Services Research Unit (PSSRU) 'Unit costs of health and social care 2013-' cost compendium [20]. Unit costs for hospital and community based health and social

care services were derived from NHS Reference costs [21] and the PSSRU [20] for the economic evaluation. The medication collected included respiratory antibiotics and steroids. The drug prescription costs were obtained from the British National Formulary [22].

The incremental cost-effectiveness of SPACE FOR COPD compared with usual care is based on EQ-5D data, as this is the utility measure currently recommended by NICE for the evaluation of cost-effectiveness of interventions used or services delivered in the public and non-public sectors [23]. The study was conducted from a National Health Service (NHS) and Personal Social Services perspective including COPD-related and all-cause healthcare costs.

Our analysis used a regression approach to better reflect the nature of the data [24]. The distribution of costs are highly skewed, so that Ordinary Least Square (OLS) assumptions of normality might not be appropriate; hence a Generalised Linear Model (GLM) was fitted for costs using a Gamma distribution and identity link function. QALYs were estimated using an OLS regression with baseline utility (EQ-5D) as a covariate, to adjust for differences between groups. This method of adjusting for baseline utility differences is more efficient than estimation of QALYs using the "change from baseline" method. Results were based on 1,000 bootstrap samples, which was sufficient to provide stable estimates of costs and effects [25].

Results were presented as Incremental Cost-effectiveness Ratio (ICER) statistics, "the cost per QALY". This is the estimated difference in mean costs between the SPACE FOR COPD and usual care arms (the Incremental Cost), divided by the difference in mean QALYs between the two arms (Incremental Effect). The ICERs can be compared against the benchmark thresholds for cost-effectiveness in the NHS context of £20,000 to £30,000 per QALY gained, as applied by NICE [26]. If the ICER is below £20,000 per QALY this suggests that the intervention is a cost-effective alternative to usual care, above £30,000 per QALY this suggests that the intervention is not cost-effective and in between these figures, the result is indeterminate. We also present the results using Incremental Net Benefit (INB) statistics, calculated by multiplying the Incremental Effects by an assumed monetary value of a QALY (the "cost-effectiveness threshold") and subtracting the Incremental Cost. We calculate INB statistics based on the two cost per QALY thresholds of £20,000 and £30,000 per QALY. A positive INB suggests that the intervention is cost-effective compared with usual care at the defined threshold.

Uncertainty over the cost-effectiveness of the intervention is reflected in an estimated probability that the INB is positive. If this figure is greater than 0.5, it indicates that the intervention is more likely to be cost-effective than not.

Results

Complete economic data regarding costs and QALYS over the six month study period were available for all patients. Mean EQ-5D utility scores for SPACE FOR COPD and usual care at baseline and six months and the mean QALYs gained are presented in Table 1. Estimated by the simple area-under-the-curve method, mean QALYs attained over the trial period based on EQ-5D utility measure were slightly lower and statistically significant for the usual care group than for SPACE FOR COPD group: -0.10 (-0.17 to -0.02). For comparison with the utility measure, we also show results based on the EQ-5D Visual Analogue Scale (VAS) (-3.05 (-8.25 to 2.14)), which provides us with a value for the participant's self-rated health at the time of survey completion on a scale of 0-100 (Table 2).

Information about the use of NHS services was obtained by GP and hospital records at six months. Reported estimates of healthcare use including prescription and diagnostic tests over 0-6 months are given in Table 3. These resource quantities were multiplied by the relevant unit costs (Table 4) to provide estimates of the mean costs per patient from 0-6 months (Table 5). Differences between the groups in the costs of healthcare use over these periods were modest, with wide confidence intervals. A summary of all included costs over the trial period is given in Table 5. This shows a difference, though non-significant, between the groups. The mean cost for the SPACE FOR COPD group was £181.39 compared with £160.65 for the usual care group: a difference of £20.74 (-£51.77 to £10.29). Overall, taking account of costs for the intervention, for prescribed medications and for other NHS services, the estimated between-group difference in costs is £27.18 (-£122.59 to £68.25) indicating reduced cost in favour of the usual care group.

The results of the incremental cost-effectiveness analysis of the SPACE FOR COPD group compared with usual care are presented in Table 6. The estimated mean healthcare cost with the intervention was approximately £30 higher than the mean cost under usual care, but there was a wide confidence interval around this estimate (-£80.19 to £134.54). The estimated difference in mean QALYs accrued over the six-month period was approximately 0.10 greater in the intervention group than in the usual care group, with a confidence interval of 0.02 to 0.17. These results suggest that the SPACE FOR COPD costs around £280.00 more per additional QALY gained compared with the usual care control.

Uncertainty surrounding the estimated costs and effects is represented on the cost-effectiveness plane (Figure 1). The joint density of incremental costs and effects straddles both east quadrants of the cost-effectiveness plane, with the majority of the points lying in the north east quadrant. This indicates that there is some degree of uncertainty surrounding both the presence and the magnitude of cost-savings and effectiveness. This uncertainty is also shown in the Cost- Effectiveness Acceptability Curve (CEAC) in Figure 2. The CEAC illustrates the probability of SPACE FOR COPD being more cost-effective than usual care at different thresholds of decision makers' willingness to pay (WTP) for a QALY. There is a 97% chance that the intervention is cost-effective at a threshold of £20,000 per QALY and 99% chance at a threshold of £30,000.

Discussion

The aim of this study was to perform an economic evaluation of a Self-Management Programme of Activity, Coping and Education in patients with COPD. The intervention showed to have a statistically significant benefit to patients' health gain (0.10 QALYs), compared to usual care. Also, it showed that there was no statistically significant difference in cost for SPACE FOR COPD compared to usual care. Analysis of the costs and effects of the self-management programme over the six month trial period indicates that this is likely to be a cost-effective use of NHS resources. At £280.39 per QALY gained, the estimated ICER is well within NICES's cost-effective thresholds of £20,000.

The results of this study indicate that the self-management programme slightly increased the use of respiratory clinic visits, emergency department visit, community physiotherapist visits, but reduced, on average, use of district nurse visits and GP visits. Our results differ to previous findings [14] which demonstrated that a pharmacy-led education and self-management programme reduced hospital days by 60%, emergency visits by 48% and unscheduled GP visits by 48% while another study of a comprehensive intervention [8] reported 42% reduction in hospital days, a 35% in accident and

emergency visits and 59% reduction in unscheduled GP visits. This difference may be due to the fact that as patients are better at self-managing their condition, they may actually use healthcare resources more because they identify when there is a problem so want help/advice to overcome it, i.e. they may be better able to identify an exacerbation, so will seek to take their exacerbation medication quicker than someone who isn't able to identify this. Also, if they are aware of the reasons for taking their medication/inhalers, then they may be more likely to actually take them as prescribed, which may increase medication costs etc. The study by Bourbeau et al [8] differed from this one because their intervention was far more intense than SPACE FOR COPD and also they recruited patients with advanced COPD and at least 1 previous hospitalisation whereas we recruited from primary care where our participants' number of hospital visits was actually rather low and the patient population was relatively mild compared to the more traditional secondary care population. Other studies [12] which recruited in secondary care and post exacerbation reported much higher number of hospital visits. Perhaps this indicates that there are differences between the patient populations in these studies which could significantly impact on healthcare resource use. Furthermore, in different healthcare systems what constitutes 'usual care' may be quite different, so what people are 'used to' or expect from care may also affect their use of resources.

In contrast with previous studies which were unable to document any benefit in term of QALYs between treatment groups, [12, 15] we did find significant differences on HRQoL and QALYs, so we can conclude that SPACE FOR COPD has a beneficial effect on patient well-being. Furthermore, our results are in line with other secondary clinical outcomes that have showed a significant change in favour of the SPACE FOR COPD intervention at six weeks (ie CRQ-SR-dyspnoea dimension) and six months (ie CRQ-SR- emotional dimension) [17].

To date there are only four studies, we are aware of, that analysed the cost-effectiveness of self-management in patients with COPD [9,12,14,28]. The Gallefoss study [9] concluded that patient education reduced costs and improved outcomes. Similarly, the cost-effectiveness analysis conducted by Effing et al, [28] showed that a self-treatment strategy was cost saving and resulted in lower probabilities for hospital admissions and healthcare contacts. Also, more recently Khmour et al., [14] proved that a pharmacist-led self-management education programme was cost saving and improved HRQoL (0.065 QALYs gain). On the other hand, the Monninkhof study [12] showed that a self-management programme costs twice as much as usual care without providing any measurable beneficial effects. The latter may partly be explained by the fact that they have used a far more expensive intervention in a relative short time horizon which might have not allowed patients benefits to become well pronounced. Comparison of the studies by Gallefoss [9] and Effing [28] with our study is difficult because they have used other outcome measured rather than QALYs thus preventing comparisons across these different programmes of care [23]. Our study differs from the above since SPACE FOR COPD is the first brief, light-touch self-management intervention to show a beneficial effect in terms of symptom burden, exercise performance, anxiety [17] and HRQoL (QALYs), with limited use of healthcare professional support.

CONCLUSION

Combining our cost-effectiveness results presented here, with the clinical analysis published elsewhere [17] we conclude that SPACE FOR COPD has resulted in significant clinical improvements (exercise performance, disease knowledge and anxiety) and a significant HRQoL gain (in terms of

QALYs) during a six-month period compared to usual care, at a cost increase of £27.18 per patient. Furthermore, SPACE FOR COPD is likely to be cost-effective for the NHS over six months at the £20,000 threshold.

SUPPORT STATEMENT

This research was funded by the National Institute for Health Research (NIHR) Research for Patient Benefit Programme (grant PB-PG-0808-17146), and Leicestershire, Northamptonshire and Rutland Collaboration for Leadership in Applied Health Research and Care, and took place at University Hospitals of Leicester National Health Service (NHS) Trust. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

CLINICAL TRIAL

This study is registered as www.controlled-trials.com with identifier number ISRCTN35501175

REFERENCES

1. The World Health Organisation. 2012. Available from: <http://www.who.int/respiratory/copd/en/>. Cited 22 July 2015 [Internet]
2. Zwerink M, Brusse-Keizer M, van der Valk PDLPM, Zielhuis GA, Monninkhof EM, van der Palen J, Frith PA, Effing T. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 3.
3. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117 (2 suppl): 1S-4S
4. Strassels S, Sullivan D, Smith DH. Characterization of the incidence and cost of COPD in the US [abstract]. Eur Respir J 1996; 9(suppl 23):421s
5. Wouters EF. Economic Analysis of the Confronting COPD Survey: overview of results. Respir Med 2003; 97(suppl C): S3- S14
6. Davies MJ, Heller S, Skinner TCM et al; Diabetes Education and Self Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008; 336(7642): 491-495
7. Effing T, Monninkhof EEM, van der Valk PP, Zielhuis GGA, Walters EH, van der Palen JJ. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4.
8. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.. Archives of Internal Medicine. 2003;163(5):585-91.

9. Gallefoss F, Bakke PS. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication?. *American Journal of Respiratory and Critical Care Medicine* 1999;160(6):2000-5.
10. Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2010 Update. <http://www.goldcopd.com> 2010.
11. National Institute for Health and Clinical Excellence (2010) Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). NICE clinical guideline 101. London: National Institute for Health and Clinical Excellence (NHS Evidence accredited). .
12. Monninkhof E, van der Valk P, van der Palen J, van Herwaarden C, Zielhuis G. Effects of a comprehensive self-management program in patients with chronic obstructive pulmonary disease. *European Respiratory Journal* 2003;22:815-20
13. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. *COPD* 2010 7(3):214-28
14. Kdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *Br J Clin Pharmacol*. 2009; 68(4): 588-598
15. Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Molken MP. Is INTERdisciplinary COMMunity-based COPD management (INTERCOM) cost-effective? *Eur Respir J* .2010 35(1):79-87
16. Disler RT, Inglis SC, Davidson PM. Non-pharmacological management interventions for COPD: an overview of Cochrane systematic reviews. *Cochrane Database of Systematic Reviews* 2013, Issue 2.
17. Mitchell KE, Johnson-Warrington V, Apps LD, Bankart J et al. A self-management programme for COPD: a randomised controlled trial. *Eur Respir J* 2014; 44: 1538-1547
18. Apps LD, Mitchell KE, Harrison SL, et al. The development and pilot testing of the Self-management Programme of Activity, Coping and Education for Chronic Obstructive Pulmonary Disease (SPACE for COPD). *Int J COPD* 2013; 8: 317-327
19. Dolan P, Gudex C, Kind P, Williams A: A social tariff for EuroQol: Results from a UK general population survey. University of York: York, Centre for Health Economics; 1995:1–19.
20. Curtis L. Unit Costs of Health and Social Care 2013: Personal Social Services Research Unit, University of Kent, 2013.
21. Department of Health. Reference costs 2012 2013 publication: Department of Health, 2013.
22. British National Formulary. British National Formulary 63. UK, 2012
23. National Institute for Health and Clinical Excellence. The social care guidance manual .London: NICE, 2013
24. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. *Health economics* 2002;11(5):415-30

25. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford: Oxford University Press, February 2007.

26. Earnshaw J, Lewis G. NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective. Pharmacoeconomics. New Zealand, 2008:725-7

27. Nguyen HQ, Gill DP, Wolpin S, Steele BG, Benditt JO. Pilot study of a cell phone-based exercise persistence intervention post-rehabilitation for COPD. International Journal of COPD 2009;4:301–13.

28. Effing T, Kerstjens H, van der Valk P, Zielhuis G, van der Palen J. Cost-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. Thorax. 2009; 64(11):956-6

29. Brooks R. EuroQol: the current state of play. *Health Policy* 1996;37(1):53-72.

30. Kaptein Ad A, Fischer MJ and Scharloo M. Self-management in patients with COPD: theoretical context, content, outcome, and integration into clinical care. Int J Chron Obstruct Pulmon Dis. 2014; 9: 907-917

31. Fletcher C.M , Elmes P. C. , Fairbairn , A. S. and Wood C. H. Significance of Respiratory Symptoms and the Diagnosis of Chronic Bronchitis in a Working Population. Br Med J. 1959 Aug 29; 2(5147): 257–266

Table 1 Mean utilities derived from the EQ-5D, and the associated mean QALYs

	Number of patients		Mean quantity (SE)		Mean treatment difference (95% CI)
	Usual care	SPACE	Usual care	SPACE	
Baseline	90	87	0.63 (0.03)	0.70 (0.02)	-0.07 (-0.14 to 0.00)
6 months	81	69	0.62 (0.03)	0.71 (0.03)	-0.08 (-0.16 to -0.01)
Change 0-6 months	78	68	0.00 (0.02)	-0.01 (0.02)	0.00 (-0.06 to 0.06)
QALYs	78	68	0.61 (0.03)	0.71 (0.03)	-0.10 (-0.17 to -0.02)

QALY: Quality-Adjusted Life Years, estimated by the area-under-the-curve for individual patients

Table 2 Mean utilities derived from the VAS scores, and the associated mean QALYs

	Number of patients		Mean quantity (SE)		Mean treatment difference (95% CI)
	Usual care	SPACE	Usual care	SPACE	
Baseline	88	82	64.3 (1.71)	66.9 (1.87)	-2.20 (-7.19 to 2.80)
6 months	81	68	65.0 (2.02)	66.2 (2.26)	-1.16 (-7.14 to 4.82)
Change 0-6 months	76	65	0.18 (1.96)	-2.68 (1.82)	2.86 (-2.49 to 8.22)
QALYs	76	65	64.58 (1.75)	67.6 (1.98)	-3.05 (-8.25 to 2.14)

QALY: Quality-Adjusted Life Years, estimated by the area-under-the-curve for individual patients

Table 3. Health care utilisation over the study period

Type of care	Number of patients		Mean quantity (SE)		Mean treatment difference (95% CI)
	Usual care	SPACE	Usual care	SPACE	
General Practitioner, surgery visit	90	85	0.96 (0.15)	0.76 (0.13)	0.19 (-0.20 to 0.58)
General Practitioner, home visit	90	85	0.08 (0.04)	0.01 (0.01)	0.07 (-0.02 to 0.15)
General Practitioner, phone	90	85	0.21 (0.06)	0.26 (0.09)	-0.05 (-0.26 to 0.16)
Community Physiotherapist, hour	90	85	0.06 (0.02)	0.08 (0.03)	-0.03 (-0.10 to 0.05)
Social worker, hour	90	85	0.01 (0.01)	0 (0)	0.01 (-0.01 to 0.03)
District nurse, hour	89	85	0.63 (0.09)	0.53 (0.08)	0.10 (-0.15 to 0.35)
District nurse, phone	90	85	0.06 (0.03)	0.02 (0.02)	0.03 (-0.03 to 0.10)
District nurse, home visit	90	84	0.37 (0.34)	0.01 (0.01)	0.35 (-0.35 to 1.06)
Clinical Decision Clinic	95	86	0.04 (0.02)	0.02 (0.02)	0.02 (-0.03 to 0.07)
Inpatient stay , episode	95	86	0.01 (0.01)	0.01 (0.01)	0 (-0.03 to 0.03)
Respiratory clinic, visit	95	86	0.08 (0.03)	0.22 (0.07)	-0.14 (-0.29 to 0.01)
Hospital nurse	95	86	0 (0)	0.02 (0.02)	-0.02 (-0.05 to 0.01)
Emergency department, visit	95	86	0.01 (0.01)	0.03 (0.02)	-0.02 (-0.07 to 0.02)
Physiotherapist department, visit	95	86	0.01 (0.01)	0.02 (0.02)	-0.01 (-0.05 to 0.02)
X-rays, test	95	86	0.17 (0.05)	0.20 (0.06)	-0.03 (-0.18 to 0.12)
CT scan, test	95	86	0.01 (0.01)	0.10 (0.04)	-0.09 (-0.17 to 0.01)
Blood tests, test	94	86	1.71 (0.40)	2.10 (0.40)	-0.39 (-1.50 to 0.72)
Spirometry test, test	95	86	0.07 (0.03)	0.10 (0.03)	-0.03 (-0.11 to 0.05)
Lung function test, test	95	86	0.02 (0.01)	0.05 (0.02)	-0.03 (-0.08 to 0.030)
Sputum test, test	95	86	0.11 (0.05)	0.20 (0.08)	-0.09 (-0.28 to 0.09)

Electrocardiogram monitoring, test	95	86	0.09 (0.03)	0.15 (0.05)	-0.06 (-0.17 to 0.05)
Urine test, test	95	86	0.35 (0.08)	0.28 (0.06)	0.07 (-0.13 to 0.26)

For Peer Review

Table 4 Unit costs of healthcare resources used

Healthcare resource	Unit cost	Details	Source of unit cost
Community care			PSSRU
GP surgery consultation	45.00	Per session	PSSRU
GP home visit	292.00	Per home visit	PSSRU
GP phone call	27.00	Per hour phone call	PSSRU
Physiotherapist	34.00	Per hour of consultation	PSSRU
Social worker	57.00	Per hour of consultation	PSSRU
District nurse surgery consultation	48.00	Per hour of consultation	PSSRU
District nurse home visit	70.00	Per hour of home visit	PSSRU
District nurse phone call	58.00	Per hour phone call	PSSRU
Hospital Services			
Clinical Decision Unit	40.00	Per session	Ref Cost
Inpatient	478.00	Per inpatient day	Ref Cost
Respiratory Clinic	154.00	Per session	Ref Cost
Nurse	75.00	Per session	Ref Cost
Emergency Department	117.00	Per session	Ref Cost
Physiotherapy	42.00	Per session	Ref Cost
X-rays	5.00	Per test	assumption
CT scan	92.00	Per test	Ref Cost
Blood tests	3.00	Per test	Ref Cost
Spirometry tests	167.00	Per test	Ref Cost
Lung function test	167.00	Per test	Ref Cost
Sputum test	7.00	Per test	Ref Cost
ECGs	53.00	Per test	Ref Cost
Urine test	4.00	Per test	Ref Cost

Ref Cost: Department of Health, NHS Reference Costs [21]

PSSRU: Personal Social Service Research Unit, Unit costs of Health and Social Care 2012-2013 [20]

Table 5 Mean NHS costs (£) of healthcare resource use over the 6 month study period

Type of care	Number of patients		Mean cost (SE)		Mean treatment difference (95% CI)
	Usual care	SPACE	Usual care	SPACE	
Intervention (therapy deliver, consumables & sessions attended)	95	89	160.65 (108.69)	181.39 (104.37)	-20.74 (-51.77 to 10.29)
NHS services					
General Practitioner, surgery visit	90	85	43 (6.59)	34.41 (5.87)	8.59 (30.10 to 47.57)
General Practitioner, home visit	90	85	22.71 (11.51)	3.44 (3.43)	19.28 (-5.02 to 43.58)
General Practitioner, phone	90	85	5.7 (1.62)	6.99 (2.40)	-1.29 (-6.95 to 4.37)
Community Physiotherapist, hour	90	85	1.89 (0.83)	2.8 (1.02)	-0.91 (-3.49 to 1.67)
Social worker, hour	90	85	0.63 (0.63)	0 (0)	0.63 (-0.65 to 1.92)
District nurse, hour	89	85	30.20 (4.43)	25.41 (3.99)	4.79 (-7.01 to 16.59)
District nurse, phone	90	85	3.22 (1.68)	1.36 (0.96)	1.86 (-2.02 to 5.73)
District nurse, home visit	90	84	25.67 (24.12)	0.83 (0.83)	24.83 (-24.48 to 74.15)
Clinical Decision Clinic	95	86	1.68 (0.83)	0.93 (0.65)	0.75 (-1.35 to 2.87)
Inpatient stay , episode	95	86	5.03 (5.03)	5.56 (5.56)	-0.53 (-15.28 to 14.23)
Respiratory clinic, visit	95	86	12.97 (4.98)	34.02 (10.92)	-21.05 (-44.02 to 1.91)
Hospital nurse	95	86	0 (0)	1.74 (1.23)	-1.74 (-4.05 to 0.56)
Emergency department, visit	95	86	1.23 (1.23)	4.08 (2.33)	-2.85 (-7.94 to 2.22)
Physiotherapist department, visit	95	86	0.44 (0.44)	0.98 (0.69)	-0.53 (-2.12 to 1.05)
X-rays, test	95	86	0.84 (0.24)	0.99 (0.30)	-0.15 (-0.90 to 0.61)
CT scan, test	95	86	0.97 (0.97)	9.63 (3.74)	-8.66 (-15.96 to -1.37)
Blood tests, test	94	86	5.14 (1.19)	6.31 (1.18)	-1.18 (-4.50 to 2.15)
Spirometry test, test	95	86	12.31 (4.50)	17.48 (5.54)	-5.17 (-19.15 to 8.81)
Lung function test, test	95	86	3.51 (2.48)	7.77 (3.81)	-4.25 (-13.10 to 4.56)
Sputum test, test	95	86	0.74 (0.32)	1.39 (0.59)	-0.65 (-1.94 to 0.64)
Electrocardiogram monitoring, test	95	86	5.02 (1.79)	8.01 (2.40)	-2.99 (-8.83 to 2.85)

Urine test, test	95	86	1.39 (0.31)	1.12(0.24)	0.27 (-0.51 to 1.05)
All NHS services	88	84	178.24 (33.6)	166.42 (25.21)	11.82 (-71.69 to 95.33)
Prescriptions					
Respiratory	95	89	59.95 (5.26)	77.07 (9.05)	-17.11 (-37.45 to 3.22)
Antibiotics	95	89	1.42 (0.22)	1.14 (0.31)	0.27 (-0.48 to 1.02)
Steroids	90	85	0.91 (0.19)	1.07 (0.39)	-0.16 (-0.99 to 0.68)
All prescriptions	90	85	62.28 (5.34)	79.28 (9.25)	-17.00 (-37.74 to 3.74)
Total cost	88	84	409.54 (351.72)	436.72 (275.72)	-27.18 (-122.59 to 68.25)

Table 6. Cost effectiveness results

Generalised Linear Model (GLM)regression				
		Mean treatment difference	95% CI	p-value
Total NHS cost (£)		27.18	(-80.19 to 134.54)	0.620
Quality-Adjusted Life Years (QALYs)		0.097	(0.02 to 0.17)	0.012
Incremental Cost Effectiveness Ratio (ICER) (£ per QALY)		280.39	(-12581 to 13142.04)	0.966
Net Monetary Benefit (NMB) (£)	£20K	1879,92		
	£30K	2845.9		
	£40K	3811.9		

Figure 1- Cost effectiveness plane, bootstrap samples using GLM




Figure 2 Cost effectiveness acceptability curve

